GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Longevity Health Holdings XAGE · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.13

+13.64%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Longevity Health Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Longevity Health Holdings is based in Pittsburgh, Pennsylvania and is incorporated in Delaware. Its shares trade on OTC under the ticker XAGE. The SEC classifies its business as soap, detergents, cleang preparations, perfumes, cosmetics. In the fiscal year to 31 December 2025, it reported revenue of $1.9m and a net loss of $6.9m. At that date it held total assets of $2.4m and shareholders' equity of −$5.9m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
29 Jul 2021
Employees
10
Head office
2403 SIDNEY STREET, SUITE 300, PITTSBURGH, PA, 15203
Incorporated in
DE
Classification
Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Rajiv ShuklaExecutive Chairman of the Board, Chief Executive Officer, since 2025$891,742
  • Mr. Patrick SturgeonNon-Executive Independent Vice Chairman of the Board$69,277
  • Mr. Bryan CassadayChief Financial Officer$303,696
  • Mr. Scott FrischIndependent Director$69,277
  • Ms. Kathryn GregoryIndependent Director$69,277
  • Dr. Gilles SpenlehauerIndependent Director$69,277
  • Mr. Richard UptonIndependent Director$69,277

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Longevity Health Holdings Inc operates from its headquarters in Pittsburgh, Pennsylvania.
  • The company employs a focused team of 10 full-time employees.
  • CT-101 Bone Healing Accelerant is designated by the FDA as a combination product.

Weaknesses

  • The company relies on a single lead product, CT-101 Bone Healing Accelerant.
  • Operations are concentrated in only one country, the United States.
  • The firm has only 10 employees, limiting operational scale.

Opportunities

  • The PBM technology is licensed from Carnegie Mellon University.
  • CT-101 is undergoing a Phase II-stage clinical trial for open tibia fractures.
  • The company can expand into various bone and soft tissue indications.

Threats

  • The company went public via an IPO in July 2021.
  • CT-101 contains B Tri-Calcium Phosphate, an already approved medical device.
  • The PBM technology uses genipin, a derivative of the gardenia plant.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.